Orforglipron and Gastroparesis: What the FDA Label Says

Orforglipron (Foundayo) slows down how quickly your stomach empties — that’s part of how it works to reduce appetite. Per its FDA-approved label on DailyMed, that same mechanism is also why orforglipron is not recommended for patients with severe gastroparesis, and why clinical trials excluded people with known gastric emptying disorders. Here’s what “delayed gastric emptying” actually means for orforglipron, how it differs from gastroparesis as a diagnosis, and what’s worth flagging to your prescriber.

Delayed gastric emptying vs. gastroparesis: not the same thing

These two terms get used interchangeably in searches, but they’re distinct:

• Delayed gastric emptying is a normal, expected, dose-related effect of GLP-1 receptor agonists like orforglipron. It’s part of the mechanism — slower stomach emptying contributes to feeling fuller longer, which is part of why these medications reduce appetite.
• Gastroparesis is a chronic medical condition involving abnormally slow stomach emptying, often with a specific underlying cause (diabetes-related nerve damage is a common one), diagnosed through specific testing rather than inferred from a medication’s mechanism.

Orforglipron’s normal pharmacological effect on gastric emptying isn’t the same as having gastroparesis. But because the two overlap mechanistically, the label treats pre-existing gastroparesis as a specific precaution rather than something to ignore.

What the FOUNDAYO label says

Per the FDA-approved label, orforglipron is not recommended in patients with severe gastroparesis, and people with known gastric emptying disorders were excluded from the clinical trials that supported its approval. That means the safety and effectiveness data behind orforglipron doesn’t include people who already had a gastric emptying disorder going in — so there’s no trial evidence to say how the drug behaves in that population.

General GLP-1 pharmacology — reflected in orforglipron’s own mechanism description — indicates the gastric-emptying effect tends to be most pronounced after the first dose and diminishes with continued use, though individual response varies and this isn’t a guarantee for any one patient.

Why this also matters for other medications you take

Because orforglipron slows how quickly things move out of the stomach, it can change how fast and how completely other oral medications you take are absorbed. The label addresses this specifically for oral hormonal contraceptives, advising a backup non-oral or barrier method during specific windows — our orforglipron and birth control guide covers those details. For other oral medications, especially ones where precise timing or blood levels matter, ask your prescriber or pharmacist whether anything about your regimen should change.

Is this a GLP-1 class effect?

Yes. Delayed gastric emptying is a mechanism shared across GLP-1 receptor agonists, not something specific to orforglipron.

	Orforglipron (Foundayo)	Semaglutide (Ozempic/Wegovy/Rybelsus)	Tirzepatide (Mounjaro/Zepbound)
Drug class	GLP-1 receptor agonist (small molecule)	GLP-1 receptor agonist (peptide)	Dual GIP/GLP-1 receptor agonist (peptide)
Delays gastric emptying	Yes	Yes	Yes
Severe gastroparesis addressed in labeling/drug info	Yes	Yes	Yes
Route	Oral tablet	Injection or oral tablet	Injection

If you’re weighing orforglipron against one of these alternatives more broadly, see Orforglipron vs Ozempic or Orforglipron vs Tirzepatide.

Symptoms worth flagging to your prescriber

This isn’t a diagnostic checklist, and it isn’t medical advice. But the symptoms most associated with gastroparesis — persistent nausea, vomiting, feeling full after eating very little, or bloating that doesn’t ease up — overlap heavily with the gastrointestinal side effects that are already common while titrating up on orforglipron. That overlap is exactly why “routine GI side effect” and “something that needs medical attention” can be hard to tell apart on your own. If something is severe, persistent, or getting worse rather than better over time, that’s worth a call to your prescriber rather than waiting it out. Our guides on managing orforglipron nausea and the full orforglipron side effects overview cover what’s typically expected during a normal titration, which can help you and your prescriber sort out what’s usual from what isn’t.

Who should bring this up before starting

If you have a history of gastroparesis, diabetic gastroparesis, or any diagnosed condition affecting stomach or intestinal motility, that’s information your prescriber needs before you start orforglipron — not something to mention only if symptoms show up later. The same goes for a history of bowel obstruction or other significant GI disease. None of that automatically rules orforglipron out, but it changes the risk conversation your prescriber needs to have with you.

What this article won’t do

This article summarizes what the FDA label and general GLP-1 pharmacology establish about delayed gastric emptying and gastroparesis — it doesn’t diagnose symptoms, estimate your personal risk, or tell you whether orforglipron is appropriate given your GI history. Those are questions for your prescriber, who has access to your full medical record and can order testing if gastroparesis is actually a concern.

Bottom line

Delaying gastric emptying is part of how orforglipron works, and that’s expected and generally diminishes over time. But it’s also why the FDA label doesn’t recommend orforglipron for severe gastroparesis and why the clinical trials behind its approval excluded people with known gastric emptying disorders. If you have a history of gastroparesis or any motility-related GI condition, raise it with your prescriber before starting — and if new or worsening GI symptoms show up once you’re on it, don’t assume it’s routine without checking in. For the broader picture of what to expect while titrating, see Foundayo (Orforglipron): A Simple Guide and First Week on Orforglipron.